Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non-Current Assets (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Other Non-Current Assets for 15 consecutive years, with $394000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 20.4% to $394000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $394000.0, a 20.4% decrease, with the full-year FY2024 number at $480000.0, changed 0.42% from a year prior.
  • Other Non-Current Assets was $394000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $479000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $501000.0 in Q3 2023 to a low of $153000.0 in Q3 2022.
  • A 5-year average of $420000.0 and a median of $477000.0 in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 67.86% in 2022, then soared 227.45% in 2023.
  • NovaBay Pharmaceuticals' Other Non-Current Assets stood at $476000.0 in 2021, then increased by 2.73% to $489000.0 in 2022, then dropped by 2.25% to $478000.0 in 2023, then increased by 0.42% to $480000.0 in 2024, then decreased by 17.92% to $394000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Non-Current Assets are $394000.0 (Q3 2025), $479000.0 (Q1 2025), and $480000.0 (Q4 2024).